SCHEMBL15401382

SCHEMBL15401382

CC1(O)CC(N)(c2ccc(Br)cc2)C1

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.39
AKT1 P31749 11/20 0.36
AKT2 P31751 11/20 0.36
TSHR P16473 1/20 0.33
KDM1A O60341 1/20 0.33
RCOR1 Q9UKL0 1/20 0.33
NOS1 P29475 1/20 0.32
CYP2A6 P11509 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15401384 1.00 TAAR1 (0.39) TAAR1AKT1AKT2TSHRKDM1A
SCHEMBL15401890 0.76 AKT1 (0.39) AKT1AKT2
SCHEMBL15401891 0.76 AKT1 (0.39) AKT1AKT2
SCHEMBL2038191 0.74 TAAR1 (0.34) TAAR1KDM1ARCOR1CYP2A6
SCHEMBL991567 0.73 CYP2A6 (0.42) TAAR1KDM1ARCOR1CYP2A6
SCHEMBL15264700 0.72 LPL (0.45)
SCHEMBL15264703 0.72 LPL (0.45)
SCHEMBL12522585 0.72 BACE1 (0.42) KDM1A
SCHEMBL15401995 0.72 AKR1C1 (0.39) TSHR
SCHEMBL15401996 0.72 AKR1C1 (0.39) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2868660-B1 ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2017-12-27 EP disclosed
US-9375434-B2 Antitumor effect potentiator composed of imidazooxazine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2016-06-28 US disclosed
CN-103459400-B Mi Zuo Bing oxazine compounds or its salt TAIHO PHARMACEUTICAL CO.,LTD. (JP) 2016-05-18 CN disclosed
US-9289431-B2 2016-03-22 US disclosed
EP-2698372-B1 NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2016-02-03 EP disclosed
US-20150164909-A1 ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
EP-2868660-A1 ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND Taiho Pharmaceutical Co., Ltd. (JP) 2015-05-06 EP disclosed
US-8772283-B2 Imidazo-oxazine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-07-08 US disclosed
EP-2698372-A1 NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2014-02-19 EP disclosed
US-20140005185-A1 NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-01-02 US disclosed
CN-103459400-A Novel imidazo-oxazine compound or salt thereof TAIHO PHARMACEUTICAL CO LTD 2013-12-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164909-A1 ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 TAAR1 1687/4885AKT1 419/4885AKT2 620/4885
US-20140005185-A1 NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF IKZF3, IKZF2, IKZF1 TAAR1 1469/4885AKT1 2351/4885AKT2 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.